Combined Blockade of Vascular Endothelial Growth Factor and Programmed Death 1 Pathways in Advanced Kidney Cancer

  Abstract: Targeted and immune-based therapies have improved outcomes in advanced kidney cancer, yet novel strategies are needed to extend the duration of these benefits and […]

Non–Clear Cell Renal Cell Carcinomas: Biological Insights and Therapeutic Challenges and Opportunities

  Abstract: The non–clear cell renal cell carcinomas (nccRCCs) are a diverse group of rare-variant renal carcinomas. Each subtype harbors a distinct cell of origin and […]

Genetic Conditions Associated With a Predisposition to Kidney Cancer

  Based on a presentation by W. Marston Linehan, MD, at the ASCO Genitourinary Cancers Symposium  Scientists have identified at least 13 genes that pre­dispose patients […]

VEGF Inhibitors in Renal Cell Carcinoma

  Abstract:  The arrival of targeted therapies—vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors—and programmed death 1 (PD-1) inhibitors has […]

Adjuvant Treatment for Renal Cell Carcinoma: Do We Finally Have a Major Breakthrough?

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Devin N. Patel, MD, Robert A. Figlin, MD, and Hyung L. Kim, MD The […]

Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

  Abstract: The incidence of renal cell carcinoma is increasing, with up to one-third of patients presenting with metastatic disease. Combination therapy is used to prolong […]